DDInter504 DDInter1934
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Desipramine {u} (Compound) resembles {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Aprindine
Aprindine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Desipramine (Compound) resembles Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Aprindine (Compound) and Aprindine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Desipramine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol